FDA Seeks OMB Approval for Wholesale Drug Distributor Data Rules

FDA Seeks OMB Approval for New Wholesale Drug Distributor & 3PL Information Collection Requirements

The FDA has submitted a proposed information collection to the Office of Management and Budget (OMB) for review under the Paperwork Reduction Act, formalizing new reporting and recordkeeping requirements for wholesale drug distributors and third-party logistics providers (3PLs). The proposal, published in the Federal Register on January 13, 2025, would codify data collection obligations under Section 584(d) and Section 583(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Supply Chain Security Act (DSCSA).

Regulatory Context

Section 584(d) of the FD&C Act requires wholesale drug distributors to maintain records and provide information to the FDA upon request. Section 583(c) imposes parallel obligations on 3PLs, which store and distribute prescription drugs on behalf of manufacturers, wholesalers, and dispensers but do not take ownership of the products. Both provisions were established under DSCSA in 2013, but the FDA has not previously formalized the scope and format of information collection through the OMB approval process required under the Paperwork Reduction Act of 1995.

The proposed information collection defines what data wholesale drug distributors and 3PLs must maintain and how they must respond to FDA requests. This includes transaction history, transaction information, and transaction statements (collectively, "T3 data") for prescription drugs distributed through the supply chain, as well as records related to licensure, suspected illegitimate product investigations, and notifications to trading partners.

Key Details

The FDA estimates the proposed information collection will affect approximately 6,500 wholesale drug distributors and 700 3PLs operating in the United States. The annual burden is projected at 1.3 million hours for wholesale drug distributors and 140,000 hours for 3PLs, reflecting the ongoing cost of maintaining electronic records in formats accessible to FDA investigators.

Specific requirements outlined in the proposal include:

For Wholesale Drug Distributors:

• Maintenance of T3 data for each transaction, stored electronically and retrievable within 48 hours of an FDA request
• Records of state licensure status, including copies of current licenses from all jurisdictions where the entity operates
• Documentation of suspicious order monitoring programs and reports of illegitimate product
• Trading partner verification records, including confirmation that manufacturers, wholesalers, and dispensers are authorized under DSCSA

For Third-Party Logistics Providers:

• Confirmation that the 3PL stores or distributes prescription drugs only for entities authorized under DSCSA
• Records identifying the location and quantity of each product stored, retrievable upon FDA request
• Documentation of state licensure or registration in jurisdictions where the 3PL operates facilities

The FDA's proposal does not establish new substantive obligations — these recordkeeping requirements already exist under DSCSA. However, OMB approval formalizes the scope and estimated burden, making the requirements enforceable under the Paperwork Reduction Act. The comment period for the OMB submission closes 30 days after Federal Register publication.

Impact Assessment

Wholesale drug distributors and 3PLs must assess whether their current data systems meet the FDA's retrieval and format expectations. The 48-hour response window for T3 data requests requires electronic recordkeeping systems capable of filtering and exporting transaction data by product, trading partner, and date range. Entities relying on paper records or legacy systems may face compliance gaps.

The proposed burden estimates — 200 hours annually per wholesale drug distributor and 200 hours per 3PL — reflect the FDA's assumption that most entities have already implemented DSCSA-compliant systems. Entities that have not yet transitioned to electronic T3 recordkeeping will face significantly higher initial costs to achieve compliance.

State licensure documentation requirements affect multi-state wholesalers and 3PLs disproportionately. An entity operating in 25 states must maintain current copies of 25 licenses, track renewal deadlines, and provide all licenses to the FDA upon request. ColdChainCheck data shows the average wholesale drug distributor in the directory holds licenses in 4.2 states, but 127 entities hold licenses in 10 or more states.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a foundational requirement under DSCSA Section 510 and a prerequisite for complying with the proposed information collection. The 41 entities without verified FDA registration represent immediate compliance gaps, as the FDA cannot enforce Section 584(d) or 583(c) obligations against unregistered entities.

The average compliance score across all tracked entities is 51/100, placing the majority in the "Fair" tier. This score reflects publicly verifiable compliance signals — state licensure, FDA registration, NABP accreditation, and enforcement history — but does not assess internal recordkeeping systems or T3 data retrieval capabilities. The proposed information collection targets operational compliance infrastructure that ColdChainCheck scores do not directly measure.

State licensure coverage varies significantly. The 127 entities operating in 10 or more states will face higher administrative burden maintaining current license documentation for FDA requests. Entities with expired or suspended licenses in any jurisdiction — reflected in lower compliance scores — risk noncompliance with the proposed recordkeeping requirements, as the FDA expects wholesalers and 3PLs to provide current licensure documentation upon request.

Practical Guidance

• Verify FDA registration status: Check that all trading partners hold active FDA establishment registrations. ColdChainCheck displays FDA registration status for each entity in the directory. Entities without verified registration may not be subject to — or capable of complying with — Section 584(d) and 583(c) obligations.

• Audit multi-state license maintenance: Entities operating in multiple jurisdictions should confirm they maintain current copies of all state licenses in a format retrievable within the FDA's expected response window. ColdChainCheck's state license data, sourced from individual state boards of pharmacy, reflects public records but does not confirm internal documentation practices.

• Review T3 data system capabilities: The 48-hour retrieval requirement assumes electronic recordkeeping. Entities relying on paper transaction records or systems without export functionality will not meet the FDA's expectations. ColdChainCheck does not assess internal data systems — this is a due diligence question for vendor qualification workflows.

• Monitor enforcement history: The 73 entities in ColdChainCheck's directory with FDA recalls or warning letters on record may face closer scrutiny under the proposed information collection. Elevated enforcement risk should trigger additional vendor qualification steps beyond baseline compliance score review.

ColdChainCheck tracks FDA enforcement actions, state licensure changes, and NABP accreditation status updates. For regulatory context on DSCSA compliance requirements, see the compliance guides section.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale drug distributors and 3PLs should consult with qualified legal counsel and verify all requirements directly with the FDA and relevant state boards of pharmacy.